RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

That actually sounds believable. The problem is, if the new POC study isn't as robust as the original trial, then they may end up saving money on the trial only to get inconclusive results due to the weaker trial design.

How likely is it that they can get a partner to sign on to foot the bill for the trial prior to an IND submission? What does this do to the up-fronts etc? In order to get the trial done, they may have to defer a decent up-front again.

This company is trapped by its undercapitalization. All the counterparties are going to continue to take advantage of this situation.